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Abstract
The coronavirus infection is an evolving pandemic with high morbidity and mortality, especially in people with comorbidities. 
The case fatality rate (CFR) is 9.2% in the presence of diabetes, while it is 1.4% in those without any comorbidity. Diabetes is 
a prevalent disease globally; hence, healthcare professionals are highly concerned about severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) pandemic progression. Current evidence does not support higher incidence of coronavirus disease 
2019 (COVID-19) in people with diabetes (PWD). However, people with diabetes are considered high risk for developing 
complications. Optimal metabolic control is a challenging concept, especially in the presence of an acute and severe respiratory 
viral infection. In this consensus, we considered the challenging issues in management of patients with diabetes during the 
COVID-19 pandemic. The consensus covers various aspects of outpatient as well as inpatient care based on the current evidence.
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The coronavirus disease 2019 (COVID-19) infection was 
first identified in December 2019 in Wuhan, China. The 
World health organization (WHO) reported 2,883,603 
confirmed cases and 198,842 confirmed deaths in 213 
countries up to April 22, 2020.1 The coronavirus infection 
is an evolving pandemic associated with high morbidity 
and mortality, especially in people with comorbidities. 
The highest mortality is reported among people over 80 
years. Moreover, presence of comorbidities is associated 
with higher case fatality rates (CFRs). The CFR is 13.2%, 
9.2%, and 8.4% in the presence of cardiovascular disease 
(CVD), diabetes, and hypertension, while it is 1.4% in 
those without any comorbidity.2
Diabetes is a prevalent disease globally; hence, 
healthcare professionals are highly concerned about severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
pandemic progression. Current evidence does not support 
higher incidence of COVID-19 in people with diabetes 
(PWD). However, the risk of complications and death is 
reported to be greater in PWD.3-6
The pathogenesis mechanisms describing the role of 
uncontrolled diabetes in prognosis of respiratory viral 
infections include high local glucose level in airway 
secretions that promotes viral replication,7 suppression of 
antiviral immune response, and increased permeability of 
alveolar epithelium vasculature8.
Therefore, glycemic control could improve clinical 
outcomes in patients with coexisting diabetes and 
COVID-19. However, appropriate metabolic control is 
a challenging concept, especially in the presence of an 
acute and severe respiratory viral infection. Furthermore, 
as diabetes is frequently associated with hypertension and 
CVD, one should also be mindful of optimally controlling 
other coexisting cardio-metabolic risk factors.
In this consensus, we considered the challenging issues 
in management of PWD during the COVID-19 infection. 
The consensus covers various aspects of outpatient as well 
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Practical Recommendations for PWD without Symptoms 
and Signs Suggestive of COVID-19
General Preventive Measures
1. Instructions should be given about personal hygiene, 
hand washing, wearing face masks, and avoidance of 
touching face, nose, and eyes.
2. Patients should be asked to avoid unnecessary travel.
3. Patients are encouraged to participate in virtual 
and online visits in order to comply with the social 
distancing rules.
4. PWD should self-quarantine and self-monitor for 14 
days, if they have been exposed to someone with the 
COVID-19 infection.
5. PWD should not take the responsibility of giving care 
to another family member (if it is possible) who is 
suspected of having the COVID-19 infection.
6. Newly diagnosed patients with diabetes should refer 
to the nearest health care center.
7. Self-quarantine provides a great opportunity to 
expand our knowledge on diabetes.
The following links would be useful for patients to find 




Maintaining Good Glycemic Control
We recommend continuing current oral glucose lowering 
drugs (OGLDs)/ injectable therapy if glucose control 
is optimal. The risk of diabetes-related complications 
increases with fluctuation of blood glucose level. In 
addition, the risk of diabetic ketoacidosis/hyperosmolar 
state coma and hypoglycemia increases significantly in 
the presence of an acute severe respiratory tract infection. 
We suggest more frequent self-monitoring of blood 
glucose (SMBG) to maintain good glycemic control. 
However, the frequency of SMBG is determined based on 
type of diabetes and treatment protocol. More frequent 
monitoring should be considered in type 1 and type 2 
diabetes mellitus (T2DM) on insulin therapy. The timing 
and intervals of SMBG need justification from the treating 
physician. Injection sites and finger-stick sites should be 
cleaned with soap or alcohol. Dry skin and finger cracking 
might occur due to using rubbing alcohol. 
Healthy Life Style
Patients should receive instructions to drink adequate 
amount of fluids and do aerobic exercises while staying 
at home. The importance of adequate protein intake 
cannot be overemphasized. Moreover, smoking should be 
avoided, as the manifestations of the coronavirus infection 
are more severe in smokers.
Treatment of CVD Risk Factors
T2DM and hypertension coexist frequently. Hence, the 
usual anti-hypertensive medications should be continued. 
Considering lack of robust evidence against use of ACE 
inhibitors or angiotensin receptor blockers, they should 
be continued in patients with the COVID-19 infection. 
Furthermore, statins should be continued if indicated.
Diabetes and Fasting during Ramadan
Considering the pandemic of COVID-19, instructions on 
fasting during Ramadan should be highly individualized. 
Treating physicians should take into account important 
variables, namely age, glycemic control status, presence 
and severity of associated co-morbidities, and type of 
regimen for glycemic control, as discussed extensively in 
international resources.9
Supplements and Vitamins
Serum vitamin D concentration is generally low in many 
populations, especially in the elderly.10, 11 Moreover, 
the reduced level of 1,25(OH)2 D affects the immune 
system. Also, vitamin D has a protective function in acute 
lung injury.12,13
Supplementing vitamin D-deficient individuals may boost 
the immune system to fight respiratory tract infection and 
reduce its severity, especially in people with associated 
co-morbidities. According to the joint statement of Iran 
Endocrine Society and Iranian Rheumatology Association, 
those who are taking monthly vitamin D supplements are 
suggested to continue their monthly 50,000-unit vitamin 
D. For those who were not taking vitamin D supplements, 
they recommend taking 50,000-unit vitamin D weekly for 
four consecutive weeks, followed by a monthly schedule.14
Telehealth during the COVID-19 Pandemic
The COVID-19 outbreak is a potential stimulus for our 
health care system to re-design the rules. Policymakers 
look for ways to ensure that patients can still access care 
while reducing the risk of coronavirus transmission. In 
this context, the healthcare system needs to develop new 
policies for telehealth services. Barriers to virtual care 
should be removed. Moreover, funding mechanisms need 
to adequately provide for the new situation.
Practical Recommendations for PWD with Uncomplicated 
COVID-19 Infection
Patients may suffer from symptoms such as fever, cough, 
sore throat, nasal congestion, malaise, and headache. The 
onset of symptoms is gradual. Although cough and fever 
are common, sore throat and runny nose are unusual. 
Dyspnea is a sign of disease severity.
 
How to Manage the Patients during Sick Days?
1. Patients should self-quarantine and self-monitor for 
14 days at home. They should wear a surgical mask 
and be isolated in a separate area.
2. Suggest adequate hydration. If they have trouble 
keeping oral intake, smaller portions every 15 minutes 
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could help to avoid dehydration.
3. Self-quarantine interferes with the healthy life style 
frequently recommended for PWD. In this context, 
more frequent SMBG is reasonable. In type 1 diabetes, 
monitoring of blood glucose should be done optimally 
at least every four hours, including during the night. 
The frequency of SMBG in T2DM depends on the 
medications used to treat diabetes. People with type 2 
diabetes who are taking oral glucose lowering drugs or 
basal insulin should monitor their blood glucose twice 
per day. Those on multiple daily injections of insulin 
should monitor blood glucose every four hours, the 
same as for type 1 diabetes. Persistently high or low 
glucose level is an indication for hospitalization.
4. OGLDs could be continued if patients could tolerate 
oral intake.
5. Metformin should be discontinued if dyspnea and 
high grade fever, and/or vomiting persists despite 
receiving supportive care.
6. In the presence of vomiting and loss of appetite, in 
order to prevent dehydration, we recommend against 
the use of sodium glucose transporter 2 inhibitors.
7. DPP4 inhibitors are reported to be well tolerated and 
can be continued, except in the presence of vomiting, 
abdominal pain, and oral feeding intolerance.
8. Considering the risk of blood glucose fluctuations, we 
recommend dose adjustment for sulfonylureas based 
on glucose profile. To reduce the risk of hypoglycemia, 
i.e. in the presence of vomiting and loss of appetite, 
discontinuing treatment is recommended.
9. To reduce the risk of hypoglycemia, we recommend 
switching glibenclamide to an acceptable alternative, 
namely gliclazide.
10. Thiazolidinediones could be continued except for 
those at risk of heart failure.
11. GLP1RA can be continued in clinically stable 
patients. It should be discontinued in the presence 
of nausea, vomiting, abdominal pain, or oral feeding 
intolerance.
12. For most patients, basal insulin is the best regimen 
for insulin initiation, if fasting glucose remains 
above goal despite optimal doses of OGLDs. Basal 
insulin analogues are safe and convenient as they are 
associated with lower risk of hypoglycemia.
13. Patients on insulin therapy should continue their 
treatment. Dose adjustment should be done based on 
SMBG diary.
14. Patients should be instructed about the warning 
symptoms of severe disease. Hospitalization is 
indicated for any of the following conditions: 
progressing dyspnea, ketone smell while breathing, 
altered consciousness, or persistently elevated blood 
glucose, i.e. BG >270 mg/dL.
15. To reduce the risk of transmission, patients are asked 
to take their own glucometer device, if hospitalization 
is necessary.
 
Treatment of Associated Co-morbidities
Blood pressure control is an essential part of managing 
diabetes. Angiotensin converting enzyme inhibitors 
(ACE-i) or Angiotensin Receptor Blockers (ARBs) 
are often recommended in patients with T2DM with 
hypertension, albuminuria, and/or CVD. At the present 
time, there is no evidence that these medications are 
associated with the risk of COVID-19 infection or its 
complications.15 We recommend neither stopping nor 
changing any of these medications. However, for patients 
at risk of dehydration, discontinuation of diuretics should 
be considered. On the other hand, statins can usually be 
continued in most cases.16
If hydroxychloroquine is being used as an off-label 
treatment in patients with moderate to severe COVID-19 
infection, clinicians should be cognizant of the risk of 
hypoglycemia. 4
 
Practical Recommendations for PWD with Severe 
COVID-19 Infection
1. Fighting against COVID-19 is a multidisciplinary 
task. The multidisciplinary teams should 
comprise nutritionists, infectious disease 
specialists, diabetologists, and respiratory disease 
specialists.
2. As PWD have worse outcomes, HCPs should be 
notified to manage hyperglycemia strictly, even if the 
patient has not been diagnosed with diabetes.
3. Frequent SMBG is recommended based on disease 
severity, tolerance of oral intake, and level of 
consciousness.
4. Considering disease severity, OGLDs should be 
discontinued and either basal-bullous insulin regimen 
or insulin infusion is recommended. Insulin infusion 
is the method of choice for glycemic control in the 
ICU setting. We recommend against the sliding scale 
regimen.
5. Cardiac and renal functions need close monitoring, 
while the patient’s condition remains critical. We 
recommend neither stopping nor changing ACE-I or 
ARBs.
6. Discharged patients should follow national rules on 




The coronavirus infection is an evolving pandemic 
associated with increased morbidity and mortality, 
especially in PWD. Appropriate preventive practice and 
intervention strategies can reduce the risk of infection and 
its mortality.
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General preventive measures including personal hygiene, 
hand washing, and wearing face masks should be followed 
by all patients. Diabetes-specific measures, namely 
adequate glycemic control, frequent SMBG, healthy life 
style, and treatment of associated comorbidities especially 
hypertension, cannot be overemphasized.
In patients with uncomplicated COVID-19, routine 
care should be continued. However, in the presence of 
severe disease, sick day rules should be applied.
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